基本信息
views: 2
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
His current research focuses on the identification and characterization of the key negative regulators, tumor suppressor proteins, of cancer development and progression, and the development of small molecule-based therapies that activate tumor suppressor genes for the treatment of cancer. To date, Dr. Narla has authored 11 patents. He has over 73 publications in journals including Nature Genetics, Science, Science Translational Medicine, Proceedings of the National Academy of Sciences, and the Journal of Clinical Investigation. His research focuses on understanding the mechanisms driving human cancer development and progression and has led to: 1) the identification of a new class of tumor suppressor genes in human cancer (the Kruppel-like factor family of genes), 2) the characterization of novel mechanisms of tumor suppressor gene inactivation in cancer progression (alternative splicing into dominant negative oncogenic splice variants), 3) the development and validation of pharmaceutically tractable strategies to reactive tumor suppressor gene function for the treatment of a broad range of human cancers, and 4) the structural, functional and biological mechanisms of PP2A inactivation in human cancer. These studies span the continuum of biomedical research starting from fundamental mechanism-driven laboratory-based studies directed at identifying novel cancer genes to the translation of these findings into the development of new drugs for cancer treatment. These novel small-molecule tumor suppressor gene activators represent the first, to our knowledge, example of drugs that directly bind and activate tumor suppressor genes for cancer treatment and provide the mechanistic and translational framework/foundation to develop entire classes of drugs directed at the key negative regulators of oncogenic signaling, an area that to date has not been the focus of major drug development efforts. He is currently the PI on two multi-PI R01 grant applications and three other NIH and DOD awards highlighting the collaborative and multi-disciplinary nature of his work. This work has also led to the formation of RAPPTA Therapeutics, a biotechnology company, seeking to develop these small molecule PP2A modulators for the treatment of cancer.
Research Interests
Papers共 281 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCER RESEARCHno. 2 (2024)
bioRxiv the preprint server for biology (2024)
Clinical Cancer Researchno. 5_Supplement (2024)
Rita A. Avelar, Riya Gupta, Grace Carvette,Felipe da Veiga Leprevost,Jose Colina,Jessica Teitel,Goutham Narla,Analisa DiFeo
Cancer Researchno. 6_Supplement (2024): 4717-4717
Samantha L Tinsley,Rebecca A Shelley, Gaganpreet K Mall, Ella Rose D Chianis,Alisha Dhiman,Garima Baral,Harish Kothandaraman,Mary C Thoma,Colin J Daniel,Nadia Atallah Lanman,Marina Pasca di Magliano,Goutham Narla,
bioRxiv : the preprint server for biology (2024)
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Load More
Author Statistics
#Papers: 0
#Citation: 0
H-Index: 0
G-Index: 0
Sociability: 0
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn